XNAS 16 Oct, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2026 | 50,246 | 119,548 | - | - | - | |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.03 per share. | 30 Sep 2026 | 50,246 | 69,302 | - | 25.0 | 1,257,657 | - |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 22.65 per share. | 14 Sep 2026 | 10,000 | 792,923 | - | 22.7 | 226,500 | Ordinary Shares |
| Mr. John W. Smither | Director | Sale of securities on an exchange or to another person at price $ 25.32 per share. | 04 Sep 2026 | 1,600 | 8,760 | - | 25.3 | 40,512 | Ordinary Shares |
| Mr. Robert William Gunning | Vice President, Controller | 01 Sep 2026 | 14,000 | 14,000 | - | - | Option (right to buy) | ||
| Mr. Robert William Gunning | Vice President, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 3,200 | 3,200 | - | 0 | Ordinary Shares | |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.91 per share. | 24 Aug 2026 | 125,000 | 69,302 | - | 26.9 | 3,363,750 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Aug 2026 | 125,000 | 194,302 | - | - | Ordinary Shares | |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | 24 Aug 2026 | 125,000 | 395,229 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.90 per share. | 20 Jul 2026 | 25,000 | 49,353 | - | 11.9 | 297,500 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | 20 Jul 2026 | 80,000 | 70,494 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | 20 Jul 2026 | 25,000 | 10,000 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 31.71 per share. | 20 Jul 2026 | 2,915 | 24,353 | - | 31.7 | 92,435 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 31.05 per share. | 20 Jul 2026 | 31,885 | 27,268 | - | 31.0 | 990,029 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 20 Jul 2026 | 70,200 | 59,153 | - | 30.0 | 2,103,192 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.17 per share. | 20 Jul 2026 | 80,000 | 129,353 | - | 11.2 | 893,600 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 22 Jun 2026 | 25,000 | 49,353 | - | 10.9 | 272,500 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 30.73 per share. | 22 Jun 2026 | 300 | 24,353 | - | 30.7 | 9,219 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.90 per share. | 22 Jun 2026 | 15,000 | 64,353 | - | 11.9 | 178,500 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | 22 Jun 2026 | 25,000 | 43,134 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | 22 Jun 2026 | 15,000 | 35,000 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 30.20 per share. | 22 Jun 2026 | 39,700 | 24,653 | - | 30.2 | 1,198,940 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.69 per share. | 26 May 2026 | 65,000 | 24,353 | - | 35.7 | 2,319,850 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | 26 May 2026 | 5,000 | 68,134 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | 26 May 2026 | 60,000 | 80,015 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 26 May 2026 | 5,000 | 89,353 | - | 10.9 | 54,500 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 26 May 2026 | 60,000 | 84,353 | - | 10 | 600,000 | Ordinary Shares |
| Mr. Louis G. Lange, M.D. | Director | Sale of securities on an exchange or to another person at price $ 31.23 per share. | 11 Mar 2026 | 446 | 10,360 | - | 31.2 | 13,929 | Ordinary Shares |
| Mr. Louis G. Lange, M.D. | Director | Sale of securities on an exchange or to another person at price $ 30.41 per share. | 11 Mar 2026 | 44,173 | 10,806 | - | 30.4 | 1,343,301 | Ordinary Shares |
| Mr. Louis G. Lange, M.D. | Director | Sale of securities on an exchange or to another person at price $ 29.41 per share. | 06 Mar 2026 | 28,186 | 0 | - | 29.4 | 828,950 | Ordinary Shares |
| Mr. Louis G. Lange, M.D. | Director | 06 Mar 2026 | 44,619 | 54,979 | - | 11.5 | 513,119 | Ordinary Shares | |
| Mr. Louis G. Lange, M.D. | Director | 06 Mar 2026 | 44,619 | 0 | - | - | Warrant (right to buy) | ||
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | 05 Mar 2026 | 94,124 | 621,638 | - | - | Option (right to buy) | ||
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | 05 Mar 2026 | 104,467 | 715,762 | - | - | Option (right to buy) | ||
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.29 per share. | 05 Mar 2026 | 101,409 | 69,302 | - | 30.3 | 3,071,679 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2026 | 101,409 | 170,711 | - | - | Ordinary Shares | |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.32 per share. | 05 Mar 2026 | 94,124 | 69,302 | - | 30.3 | 2,853,840 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2026 | 94,124 | 163,426 | - | - | Ordinary Shares | |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.30 per share. | 05 Mar 2026 | 104,467 | 69,302 | - | 30.3 | 3,165,350 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2026 | 104,467 | 173,769 | - | - | Ordinary Shares | |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | 05 Mar 2026 | 101,409 | 520,229 | - | - | Option (right to buy) | ||
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.25 per share. | 02 Mar 2026 | 443,707 | 174,144 | - | 33.3 | 14,753,258 | Ordinary Shares |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2026 | 443,707 | 617,851 | - | - | Ordinary Shares | |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | 02 Mar 2026 | 443,707 | 239,267 | - | - | Option (right to buy) | ||
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 183,332 | 643,191 | - | - | Ordinary Shares | |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.68 per share. | 24 Feb 2026 | 1,300 | 459,859 | - | 36.7 | 47,684 | Ordinary Shares |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.96 per share. | 24 Feb 2026 | 10,436 | 461,159 | - | 36.0 | 375,279 | Ordinary Shares |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.11 per share. | 24 Feb 2026 | 46,517 | 471,595 | - | 35.1 | 1,633,212 | Ordinary Shares |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 58,253 | 518,112 | - | - | Ordinary Shares | |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.46 per share. | 24 Feb 2026 | 3,161 | 459,859 | - | 36.5 | 115,250 | Ordinary Shares |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.13 per share. | 24 Feb 2026 | 61,547 | 463,020 | - | 36.1 | 2,223,693 | Ordinary Shares |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2026 | 64,708 | 524,567 | - | - | Ordinary Shares | |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | 24 Feb 2026 | 183,332 | 682,974 | - | - | Option (right to buy) | ||
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | 24 Feb 2026 | 58,253 | 866,306 | - | - | Option (right to buy) | ||
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | 24 Feb 2026 | 64,708 | 924,559 | - | - | Option (right to buy) | ||
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.44 per share. | 24 Feb 2026 | 17,924 | 174,144 | - | 34.4 | 617,303 | Ordinary Shares |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.63 per share. | 24 Feb 2026 | 165,408 | 477,783 | - | 33.6 | 5,562,671 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 20 Feb 2026 | 14,692 | 84,289 | - | 35 | 514,220 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.46 per share. | 20 Feb 2026 | 30,789 | 53,500 | - | 35.5 | 1,091,778 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 31.80 per share. | 27 Jan 2026 | 32,612 | 24,353 | - | 31.8 | 1,037,062 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 27 Jan 2026 | 32,612 | 56,965 | - | 10.9 | 355,471 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 32.62 per share. | 27 Jan 2026 | 39,816 | 24,353 | - | 32.6 | 1,298,798 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 27 Jan 2026 | 39,816 | 64,169 | - | 10.9 | 433,994 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | 27 Jan 2026 | 32,612 | 73,134 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | 27 Jan 2026 | 39,816 | 105,746 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 23 Jan 2026 | 38,172 | 62,525 | - | 10.9 | 416,075 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | 23 Jan 2026 | 38,172 | 179,962 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | 23 Jan 2026 | 34,400 | 145,562 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 33.45 per share. | 23 Jan 2026 | 309 | 24,353 | - | 33.4 | 10,336 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 32.77 per share. | 23 Jan 2026 | 34,091 | 24,662 | - | 32.8 | 1,117,162 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 23 Jan 2026 | 34,400 | 58,753 | - | 10.9 | 374,960 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 34.37 per share. | 23 Jan 2026 | 12,767 | 24,353 | - | 34.4 | 438,802 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 33.44 per share. | 23 Jan 2026 | 25,405 | 37,120 | - | 33.4 | 849,543 | Ordinary Shares |
| Mr. Ian Somaiya | Chief Financial Officer | 20 Jan 2026 | 39,784 | 662,814 | - | - | Option (Right to Buy) | ||
| Mr. Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.26 per share. | 20 Jan 2026 | 60,216 | 118,598 | - | 9.3 | 557,600 | Ordinary Shares |
| Mr. Ian Somaiya | Chief Financial Officer | 20 Jan 2026 | 60,216 | 702,598 | - | - | Option (Right to Buy) | ||
| Mr. Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.80 per share. | 20 Jan 2026 | 24,362 | 58,382 | - | 33.8 | 823,436 | Ordinary Shares |
| Mr. Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.25 per share. | 20 Jan 2026 | 15,422 | 82,744 | - | 33.3 | 512,782 | Ordinary Shares |
| Mr. Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.26 per share. | 20 Jan 2026 | 39,784 | 98,166 | - | 9.3 | 368,400 | Ordinary Shares |
| Mr. Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.38 per share. | 20 Jan 2026 | 19,604 | 58,382 | - | 32.4 | 634,778 | Ordinary Shares |
| Mr. Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.78 per share. | 20 Jan 2026 | 39,712 | 77,986 | - | 31.8 | 1,262,047 | Ordinary Shares |
| Mr. Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.64 per share. | 20 Jan 2026 | 900 | 117,698 | - | 30.6 | 27,576 | Ordinary Shares |
| Mr. Louis G. Lange, M.D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 3,400 | 10,360 | - | - | Ordinary Shares | |
| Mr. Louis G. Lange, M.D. | Director | 07 Jan 2026 | 15,300 | 15,300 | - | - | Option (right to buy) | ||
| Mr. William H. Lewis, J.D.,M.B.A. | Director | 07 Jan 2026 | 15,300 | 15,300 | - | - | Option (right to buy) | ||
| Mr. William H. Lewis, J.D.,M.B.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 3,400 | 10,360 | - | - | Ordinary Shares | |
| Mr. John W. Smither | Director | 07 Jan 2026 | 15,300 | 15,300 | - | - | Option (right to buy) | ||
| Mr. John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 3,400 | 10,360 | - | - | Ordinary Shares | |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 07 Jan 2026 | 11,582 | 378,859 | - | - | Ordinary Shares | |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 81,000 | 459,859 | - | - | Ordinary Shares | |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | 07 Jan 2026 | 364,000 | 364,000 | - | - | Option (right to buy) | ||
| Ms. Adele M. Gulfo | Director | 07 Jan 2026 | 15,300 | 15,300 | - | - | Option (right to buy) | ||
| Ms. Adele M. Gulfo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 3,400 | 14,260 | - | - | Ordinary Shares | |
| Mr. Mark C. McKenna | Director | 07 Jan 2026 | 15,300 | 15,300 | - | - | Option (right to buy) | ||
| Mr. Mark C. McKenna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 3,400 | 10,360 | - | - | Ordinary Shares | |
| Ms. Janneke van der Kamp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 3,400 | 10,360 | - | - | Ordinary Shares | |
| Ms. Janneke van der Kamp | Director | 07 Jan 2026 | 15,300 | 15,300 | - | - | Option (right to buy) | ||
| Mr. Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.25 per share. | 05 Jan 2026 | 5,118 | 32,882 | - | 33.3 | 170,174 | Ordinary Shares |
| Mr. Ian Somaiya | Chief Financial Officer | 05 Jan 2026 | 115,000 | 115,000 | - | - | Option (right to buy) | ||
| Mr. Ian Somaiya | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2026 | 25,500 | 58,382 | - | - | Ordinary Shares | |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | 05 Jan 2026 | 115,000 | 115,000 | - | - | Option (right to buy) | ||
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.25 per share. | 05 Jan 2026 | 6,000 | 73,481 | - | 33.3 | 199,500 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2026 | 25,500 | 98,981 | - | - | Ordinary Shares | |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 33.25 per share. | 05 Jan 2026 | 2,647 | 12,353 | - | 33.3 | 88,013 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | 05 Jan 2026 | 53,500 | 53,500 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2026 | 12,000 | 24,353 | - | - | Ordinary Shares | |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 23 Dec 2025 | 75,117 | 90,117 | - | 10 | 751,170 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | 23 Dec 2025 | 5,000 | 218,134 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | 23 Dec 2025 | 38,872 | 140,015 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | 23 Dec 2025 | 26,011 | 178,887 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | 23 Dec 2025 | 75,117 | 204,898 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.30 per share. | 23 Dec 2025 | 43,872 | 15,000 | - | 35.3 | 1,548,682 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 23 Dec 2025 | 5,000 | 58,872 | - | 10.9 | 54,500 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 23 Dec 2025 | 38,872 | 53,872 | - | 10 | 388,720 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 35.68 per share. | 23 Dec 2025 | 26,011 | 15,000 | - | 35.7 | 928,072 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 23 Dec 2025 | 26,011 | 41,011 | - | 10 | 260,110 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 36.21 per share. | 23 Dec 2025 | 75,117 | 15,000 | - | 36.2 | 2,719,987 | Ordinary Shares |
| Dr. James N. Topper, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 23.70 per share. | 15 Sep 2025 | 660 | 3,028,524 | - | 23.7 | 15,639 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 26.11 per share. | 09 Sep 2025 | 96,896 | 15,000 | - | 26.1 | 2,529,955 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.31 per share. | 09 Sep 2025 | 53,104 | 111,896 | - | 25.3 | 1,344,062 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 09 Sep 2025 | 150,000 | 165,000 | - | 10 | 1,500,000 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | 09 Sep 2025 | 150,000 | 280,015 | - | - | Option (right to buy) | ||
| Dr. James N. Topper, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 24.99 per share. | 08 Sep 2025 | 1,260 | 3,027,864 | - | 25.0 | 31,487 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 25.09 per share. | 03 Sep 2025 | 18,073 | 15,000 | - | 25.1 | 453,452 | Ordinary Shares |
| Ms. Louise Kooij | Chief Accounting Officer | 02 Sep 2025 | 18,073 | 0 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 18,073 | 33,073 | - | - | Ordinary Shares | |
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 24.86 per share. | 25 Aug 2025 | 8,269 | 15,000 | - | 24.9 | 205,567 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.08 per share. | 21 Aug 2025 | 42,342 | 76,960 | - | 25.1 | 1,061,937 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.49 per share. | 21 Aug 2025 | 7,658 | 69,302 | - | 25.5 | 195,202 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.29 per share. | 21 Aug 2025 | 50,000 | 119,302 | - | 24.3 | 1,214,500 | Ordinary Shares |
| Dr. James N. Topper, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 23.98 per share. | 11 Aug 2025 | 471 | 3,026,604 | - | 24.0 | 11,294 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 15 Jul 2025 | 47,569 | 91,569 | - | 10.9 | 518,502 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | 15 Jul 2025 | 51,043 | 162,702 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | 15 Jul 2025 | 47,569 | 213,745 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 21.10 per share. | 15 Jul 2025 | 51,043 | 44,000 | - | 21.1 | 1,077,007 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 15 Jul 2025 | 51,043 | 95,043 | - | 10.9 | 556,369 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 22.12 per share. | 15 Jul 2025 | 3,544 | 44,000 | - | 22.1 | 78,393 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 21.38 per share. | 15 Jul 2025 | 44,025 | 47,544 | - | 21.4 | 941,255 | Ordinary Shares |
| Dr. James N. Topper, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 18.43 per share. | 24 Jun 2025 | 2,520 | 3,024,873 | - | 18.4 | 46,454 | Ordinary Shares |
| Dr. James N. Topper, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 18.26 per share. | 24 Jun 2025 | 1,260 | 3,026,133 | - | 18.3 | 23,012 | Ordinary Shares |
| Dr. James N. Topper, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 19.50 per share. | 16 Jun 2025 | 8,584 | 3,022,153 | - | 19.5 | 167,381 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | 16 Jun 2025 | 21,899 | 261,314 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | 16 Jun 2025 | 78,101 | 372,829 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 19.19 per share. | 16 Jun 2025 | 81,891 | 62,109 | - | 19.2 | 1,571,488 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.90 per share. | 16 Jun 2025 | 21,899 | 144,000 | - | 10.9 | 238,699 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 16 Jun 2025 | 78,101 | 122,101 | - | 10 | 781,010 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 19.75 per share. | 16 Jun 2025 | 18,109 | 44,000 | - | 19.8 | 357,653 | Ordinary Shares |
| Mr. Louis G. Lange, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2025 | 68 | 28,186 | - | 0 | Ordinary Shares | |
| Mr. Louis G. Lange, M.D. | Director | 01 Jun 2025 | 68 | 0 | - | - | Restricted Stock Unit | ||
| Mr. Douglas F. Kling | Chief Operating Officer | 15 May 2025 | 100,000 | 450,930 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 15 May 2025 | 100,000 | 144,000 | - | 10 | 1,000,000 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 May 2025 | 100,000 | 44,000 | - | - | Ordinary Shares | |
| Mr. Louis G. Lange, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 69 | 28,118 | - | 0 | Ordinary Shares | |
| Mr. Louis G. Lange, M.D. | Director | 01 May 2025 | 69 | 68 | - | - | Restricted Stock Unit | ||
| Ms. Juliette Audet | See Remarks | 01 May 2025 | 30,000 | 30,000 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 Apr 2025 | 910 | 44,000 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 Apr 2025 | 99,090 | 44,910 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 15 Apr 2025 | 100,000 | 144,000 | - | 10 | 1,000,000 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | 15 Apr 2025 | 100,000 | 550,930 | - | - | Option (right to buy) | ||
| Ms. Adele M. Gulfo | Director | 15 Apr 2025 | 50,700 | 50,700 | - | - | Option (right to buy) | ||
| Ms. Adele M. Gulfo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2025 | 10,860 | 10,860 | - | - | Ordinary Shares | |
| Mr. Louis G. Lange, M.D. | Director | 14 Apr 2025 | 69 | 137 | - | - | Restricted Stock Unit | ||
| Mr. Louis G. Lange, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2025 | 69 | 28,049 | - | 0 | Ordinary Shares | |
| Dr. James N. Topper, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 22.49 per share. | 26 Mar 2025 | 1,135 | 3,013,569 | - | 22.5 | 25,521 | Ordinary Shares |
| Mr. Louis G. Lange, M.D. | Director | 26 Mar 2025 | 3,308 | 3,308 | - | - | Restricted Stock Unit | ||
| Mr. Louis G. Lange, M.D. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 3,102 | 10,062 | - | 0 | Ordinary Shares | |
| Mr. Louis G. Lange, M.D. | Director | 26 Mar 2025 | 3,102 | 206 | - | - | Restricted Stock Unit | ||
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 38,394 | 402,699 | - | 0 | Ordinary Shares | |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 30,992 | 364,305 | - | 0 | Ordinary Shares | |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | 26 Mar 2025 | 38,394 | 0 | - | - | Restricted Stock Unit | ||
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 26 Mar 2025 | 12,258 | 390,441 | - | - | Ordinary Shares | |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | 26 Mar 2025 | 38,394 | 38,394 | - | - | Restricted Stock Unit | ||
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 26 Mar 2025 | 16,539 | 44,000 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | 26 Mar 2025 | 16,539 | 0 | - | - | Restricted Stock Unit | ||
| Mr. Douglas F. Kling | Chief Operating Officer | 26 Mar 2025 | 16,539 | 16,539 | - | - | Restricted Stock Unit | ||
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 16,539 | 60,539 | - | 0 | Ordinary Shares | |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 19,302 | 169,302 | - | 0 | Ordinary Shares | |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 45,481 | 79,481 | - | 0 | Ordinary Shares | |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | 26 Mar 2025 | 45,481 | 45,481 | - | - | Restricted Stock Unit | ||
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | 26 Mar 2025 | 45,481 | 0 | - | - | Restricted Stock Unit | ||
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 8,269 | 23,269 | - | 0 | Ordinary Shares | |
| Ms. Louise Kooij | Chief Accounting Officer | 26 Mar 2025 | 8,269 | 8,269 | - | - | Restricted Stock Unit | ||
| Ms. Louise Kooij | Chief Accounting Officer | 26 Mar 2025 | 8,269 | 0 | - | - | Restricted Stock Unit | ||
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | 24 Mar 2025 | 150,000 | 820,229 | - | - | Option (right to buy) | ||
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2025 | 150,000 | 150,000 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 17 Mar 2025 | 100,000 | 44,000 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | 17 Mar 2025 | 11,888 | 650,930 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | 17 Mar 2025 | 88,112 | 47,251 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 17 Mar 2025 | 11,888 | 144,000 | - | 10 | 118,880 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Mar 2025 | 88,112 | 132,112 | - | - | Ordinary Shares | |
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 150,000 | 165,000 | - | - | Ordinary Shares | |
| Ms. Louise Kooij | Chief Accounting Officer | 04 Mar 2025 | 150,000 | 18,073 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 20.37 per share. | 04 Mar 2025 | 150,000 | 15,000 | - | 20.4 | 3,055,500 | Ordinary Shares |
| Dr. James N. Topper, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 21.02 per share. | 04 Mar 2025 | 4,005 | 3,012,434 | - | 21.0 | 84,203 | Ordinary Shares |
| Mr. Douglas F. Kling | Chief Operating Officer | 18 Feb 2025 | 9,218 | 126,145 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | 18 Feb 2025 | 90,782 | 135,363 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 Feb 2025 | 9,218 | 44,000 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 9,218 | 53,218 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 Feb 2025 | 90,782 | 44,000 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 90,782 | 134,782 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | 29 Jan 2025 | 13,578 | 226,145 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 56,863 | 100,863 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 29 Jan 2025 | 56,863 | 44,000 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 29 Jan 2025 | 8,914 | 44,000 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 29 Jan 2025 | 4,664 | 52,914 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2025 | 13,578 | 57,578 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | 29 Jan 2025 | 56,863 | 239,723 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | 27 Jan 2025 | 104,174 | 321,971 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | 27 Jan 2025 | 25,385 | 296,586 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 104,174 | 148,174 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 80,359 | 67,815 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 23,815 | 44,000 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 25,385 | 69,385 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 20,237 | 49,148 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 5,148 | 44,000 | - | - | Ordinary Shares | |
| Mr. Ian Somaiya | Chief Financial Officer | 27 Jan 2025 | 14,900 | 762,814 | - | - | Option (Right to Buy) | ||
| Mr. Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.26 per share. | 27 Jan 2025 | 14,900 | 52,900 | - | 9.3 | 137,974 | Ordinary Shares |
| Mr. Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 11,495 | 41,405 | - | - | Ordinary Shares | |
| Mr. Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 3,405 | 38,000 | - | - | Ordinary Shares | |
| Mr. Ian Somaiya | Chief Financial Officer | 27 Jan 2025 | 46,983 | 777,714 | - | - | Option (Right to Buy) | ||
| Mr. Ian Somaiya | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.26 per share. | 27 Jan 2025 | 46,983 | 84,983 | - | 9.3 | 435,063 | Ordinary Shares |
| Mr. Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 13,304 | 38,000 | - | - | Ordinary Shares | |
| Mr. Ian Somaiya | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 27 Jan 2025 | 33,679 | 51,304 | - | - | Ordinary Shares | |
| Mr. William Jones, Jr | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 43,000 | 43,000 | - | - | Ordinary Shares | |
| Mr. Douglas F. Kling | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 44,000 | 44,000 | - | - | Ordinary Shares | |
| Mr. Ian Somaiya | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 38,000 | 38,000 | - | - | Ordinary Shares | |
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 34,000 | 34,000 | - | - | Ordinary Shares | |
| Ms. Juliette Audet | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 14,000 | 15,104 | - | - | Ordinary Shares | |
| Ms. Louise Kooij | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 15,000 | 15,000 | - | - | Ordinary Shares | |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | 06 Jan 2025 | 670,467 | 670,467 | - | - | Option (right to buy) | ||
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 123,529 | 123,529 | - | - | Ordinary Shares | |
| Mr. Louis G. Lange, M.D. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 6,960 | 6,960 | - | - | Ordinary Shares | |
| Mr. Louis G. Lange, M.D. | Director | 06 Jan 2025 | 32,500 | 32,500 | - | - | Option (right to buy) | ||
| Mr. William H. Lewis, J.D.,M.B.A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 6,960 | 6,960 | - | - | Ordinary Shares | |
| Mr. William H. Lewis, J.D.,M.B.A. | Director | 06 Jan 2025 | 32,500 | 32,500 | - | - | Option (right to buy) | ||
| Mr. John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 6,960 | 6,960 | - | - | Ordinary Shares | |
| Mr. John W. Smither | Director | 06 Jan 2025 | 32,500 | 32,500 | - | - | Option (right to buy) | ||
| Mr. Mark C. McKenna | Director | 06 Jan 2025 | 32,500 | 32,500 | - | - | Option (right to buy) | ||
| Mr. Mark C. McKenna | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 6,960 | 6,960 | - | - | Ordinary Shares | |
| Ms. Janneke van der Kamp | Director | 06 Jan 2025 | 32,500 | 32,500 | - | - | Option (right to buy) | ||
| Ms. Janneke van der Kamp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 6,960 | 6,960 | - | - | Ordinary Shares | |
| Mr. William Jones, Jr | Chief Commercial Officer | 02 Jan 2025 | 200,000 | 200,000 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | 02 Jan 2025 | 250,000 | 250,000 | - | - | Option (right to buy) | ||
| Mr. Ian Somaiya | Chief Financial Officer | 02 Jan 2025 | 220,000 | 220,000 | - | - | Option (right to buy) | ||
| Dr. Johannes Jacob Pieter Kastelein, F.E.S.C.,M.D.,PhD | Director, Chief Scientific Officer | 02 Jan 2025 | 200,000 | 200,000 | - | - | Option (right to buy) | ||
| Ms. Juliette Audet | Chief Business Officer | 02 Jan 2025 | 100,000 | 100,000 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | 02 Jan 2025 | 80,000 | 80,000 | - | - | Option (right to buy) | ||
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | 09 Oct 2024 | 15,000 | 85,000 | - | - | Warrant (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2024 | 45,000 | 45,000 | - | - | Ordinary Shares | |
| Ms. Louise Kooij | Chief Accounting Officer | 27 Sep 2024 | 45,000 | 168,073 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 15.72 per share. | 27 Sep 2024 | 45,000 | 0 | - | 15.7 | 707,400 | Ordinary Shares |
| Ms. Juliette Audet | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 15.70 per share. | 26 Sep 2024 | 1,104 | 1,104 | - | 15.7 | 17,333 | Ordinary Shares |
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 16.27 per share. | 20 Aug 2024 | 5,000 | 209,784 | - | 16.3 | 81,350 | Ordinary Shares |
| Mr. Mark C. McKenna | Director | 17 Jul 2024 | 72,500 | 72,500 | - | - | Option (right to buy) | ||
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 17.26 per share. | 20 Jun 2024 | 5,000 | 204,784 | - | 17.3 | 86,309 | Ordinary Shares |
| Ms. Juliette Audet | Chief Business Officer | 01 Apr 2024 | 250,000 | 250,000 | - | - | Option (right to buy) | ||
| Dr. Johannes Jacob Pieter Kastelein, M.D. | Director, Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.72 per share. | 26 Mar 2024 | 11,197 | 190,476 | - | 22.7 | 254,396 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, M.D. | Director, Chief Scientific Officer | 26 Mar 2024 | 201,673 | 970,229 | - | - | Option (right to buy) | ||
| Dr. Johannes Jacob Pieter Kastelein, M.D. | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 26 Mar 2024 | 190,476 | 0 | - | 21.5 | 4,095,234 | Ordinary Shares |
| Dr. Johannes Jacob Pieter Kastelein, M.D. | Director, Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 201,673 | 201,673 | - | - | Ordinary Shares | |
| Dr. James N. Topper, M.D.,PhD | Director | Purchase of securities on an exchange or from another person at price $ 21.50 per share. | 26 Mar 2024 | 8,429 | 3,008,429 | - | 21.5 | 181,224 | Ordinary Shares |
| Mr. Louis G. Lange, M.D. | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 13 Feb 2024 | 5,000 | 24,878 | - | 19 | 95,000 | Ordinary Shares |
| Mr. William H. Lewis, J.D.,M.B.A. | Director | 04 Jan 2024 | 100,000 | 100,000 | - | - | Option (right to buy) | ||
| Dr. Michael Harvey Davidson, M.D. | Director, Chief Executive Officer | 01 Jan 2024 | 1,039,939 | 1,039,939 | - | - | Option (right to buy) | ||
| Ms. Janneke van der Kamp | Director | 01 Jan 2024 | 10,000 | 10,000 | - | - | Option (right to buy) | ||
| Dr. Johannes Jacob Pieter Kastelein, M.D. | Director, Chief Scientific Officer | 01 Jan 2024 | 500,000 | 500,000 | - | - | Option (right to buy) | ||
| Mr. John W. Smither | Director | 01 Jan 2024 | 10,000 | 10,000 | - | - | Option (right to buy) | ||
| Mr. Louis G. Lange, M.D. | Director | 01 Jan 2024 | 10,000 | 10,000 | - | - | Option (right to buy) | ||
| Ms. Louise Kooij | Chief Accounting Officer | 01 Jan 2024 | 150,494 | 150,494 | - | - | Option (right to buy) | ||
| Mr. Douglas F. Kling | Chief Operating Officer | 01 Jan 2024 | 323,771 | 323,771 | - | - | Option (right to buy) | ||
| Mr. Ian Somaiya | Chief Financial Officer | 01 Jan 2024 | 80,000 | 80,000 | - | - | Option (right to buy) |